Group 1 - The company plans to acquire 90% of Shudun Information Technology Co., Ltd. through a combination of issuing shares and cash payment, along with raising supporting funds, which is expected to meet the criteria for a major asset restructuring as per the regulations [2] - The transaction is classified as a related party transaction but will not result in a change of control for the company [2] - The company’s stock was suspended from trading starting November 24, 2025, with an expected suspension period of no more than five trading days [3] Group 2 - Due to the complexity of the transaction, the company applied for an extension of the trading suspension, which will continue until at least December 1, 2025 [3][4] - On December 5, 2025, the company’s board approved the proposal for the acquisition and related funding, with the stock expected to resume trading on December 8, 2025 [4] - As of January 6, 2026, the company reported that due diligence, auditing, and evaluation related to the transaction are progressing smoothly [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司于2026年2月4日召开的第六届董事会2026年第一次独立董事专门会议审议通过了《关于2026年度子 公司向金融机构申请授信额度及公司为子公司提供担保额度预计的议案》，独立董事一致同意将该议案 提交董事会审议。经认真审阅有关文件及了解相关情况，独立董事发表了如下意见：本次担保系基于子 公司（含授权期限内新设立或纳入合并范围的子公司）拟向金融机构申请综合授信所发生的担保，被担 保方均为公司合并报表范围内的子公司，公司能够全面了解被担保方的经营管理情况、偿还债务的能 力，公司为其提供担保的财务风险处于可控范围内，不会对公司的正常运作和业务发展产生不利影响， 因此，本事项不存在损害公司和全体股东，特别是中小股东利益的情形。本次担保额度预计事项的决策 和审议程序合法合规。 七、累计对外担保数量及逾期担保的数量 截至本公告日，公司担保均为合并报表范围内的担保。本次担保后，公司及子公司担保额度总金额为 79,000万元，占公司最近一期经审计净资产的84.85%；截止目前实际担保余额为39,246.88万元，占公司 最近一期经审计净资产的42.15%。前述担保总额不等于 ...

证券代码：600821 证券简称：金开新能 公告编号：2026-009 关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 金开新能源股份有限公司 二、公司前十大无限售条件股东持股情况 公司前十大无限售条件股东持股情况与公司前十大股东持股情况一致。 金开新能源股份有限公司（以下简称"金开新能"或"公司"）于2026年1月23日召开第十一届董事会第十 六次会议，审议通过《关于以集中竞价交易方式回购公司股份的议案》，具体内容详见公司于2026年1 月24日在上海证券交易所网站披露的《关于以集中竞价交易方式回购股份的预案》（公告编号：2026- 004）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司2026年第一次临时股东会股权登记日（即2026年2月2日）登记在册的前十大股东和前十 大无限售条件股东的名称及持股数量、比例情况公告如下： 一、公司前十大股东持股情况 ■ 注: 天津津诚二号股权投资基金合伙企业（有 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300846 证券简称：首都在线 公告编号：2026-005 北京首都在线科技股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 北京首都在线科技股份有限公司（以下简称"公司"或"首都在线"）第六届董事会第十二次会议于2026年 2月4日在公司会议室以现场与通讯相结合的方式召开。会议通知于2026年1月30日以邮件方式送达各位 董事，各位董事确认收悉。本次会议应出席董事7人，实际出席董事7人。本次会议由公司董事长曲宁先 生主持，公司高级管理人员列席会议，其中董事曲宁先生、姚巍先生、杨丽萍女士、赵永志先生、赵西 卜先生、石静霞女士、刘云淮先生以通讯表决方式出席本次会议。本次会议的召集、召开、议案审议程 序符合《中华人民共和国公司法》（以下简称"《公司法》"）和《北京首都在线科技股份有限公司章 程》（以下简称"《公司章程》"）等有关规定，会议程序和结果合法有效。 二、会议表决情况 经与会董事审议，以投票表决的方式通过了以下议案： （一）审议通过《关于 ...

Core Viewpoint - The company has received approval for the listing application of the chemical raw material drug, Ferric Protein Succinylate, which marks a significant advancement in its raw material drug sector and supports its integrated development strategy in raw material and formulation [1][3]. Group 1: Drug Approval Details - The chemical raw material drug approved is Ferric Protein Succinylate, with a packaging specification of 10kg/bag and registration number Y20230001210 [1]. - The approval was granted by the National Medical Products Administration, confirming that the drug meets the relevant requirements for drug registration [1]. Group 2: R&D Investment - The company has invested approximately RMB 8.34 million (about 834.23 thousand) in the research and development of the Ferric Protein Succinylate project as of the announcement date [2]. Group 3: Market Position - As of the announcement date, there are 11 companies in China with an "A" registration status for Ferric Protein Succinylate, including the company and Jichuan Pharmaceutical Group [2]. Group 4: Strategic Impact - The approval of Ferric Protein Succinylate is expected to enhance the company's control over its raw material production and enrich its product structure, aligning with its strategic goals [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001255 证券简称：博菲电气 公告编号：2026-016 浙江博菲电气股份有限公司 关于2025年限制性股票激励计划预留授予 限制性股票授予登记完成的公告（新增股份） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、上市日（新增股份）：2026年2月9日 2、登记数量（新增股份）：67.20万股 3、授予价格：12.98元/股 4、授予登记人数（新增股份）：4人 5、授予的股票来源（新增股份）：公司向激励对象定向发行的本公司人民币A股普通股 （四）2025年5月29日，公司召开第三届董事会第十五次会议、第三届监事会第十二次会议，审议通过 了《关于调整公司2025年限制性股票激励计划相关事项的议案》《关于向公司2025年限制性股票激励计 划激励对象首次授予限制性股票的议案》。公司监事会对激励对象名单进行了核查并发表了意见。 （五）2025年11月28日，公司召开第三届董事会第二十二次会议、第三届监事会第十七次会议，审议通 过了《关于回购注销2025年限制性股票激励计划部分限制性股 ...

Group 1 - The company held its sixth board meeting on July 5, 2024, where it approved adjustments to the stock option incentive plans for 2018, 2019, 2021, and 2022, including changes to exercise prices and the cancellation of certain stock options from the 2019 plan [1][12][24] - The number of initial grant incentive recipients was adjusted from 310 to 298, and the total number of stock options granted was reduced from 15,605,490 to 15,238,124, with the exercise price changed from 13.35 CNY to 13.05 CNY [1][12] - The board recognized that the exercise conditions for the fifth exercise period of the 2019 stock option incentive plan had been met, allowing 298 recipients to exercise their options at the adjusted price [1][12] Group 2 - On December 20, 2024, the company held its sixth board meeting where it approved the cancellation of stock options from the 2019 incentive plan that were unlocked but not exercised [2][14] - The cancellation was due to the failure of incentive recipients to fully exercise their options within the exercise period [2][14] Group 3 - The company held its fifth board meeting on September 30, 2021, where it approved the 2021 stock option incentive plan, which was deemed beneficial for the company's sustainable development [3][20] - The plan included the granting of 52,419,000 stock options to 1,097 recipients, with the initial grant date set for December 3, 2021 [5][21] Group 4 - The company adjusted the exercise price of the 2021 stock option incentive plan from 35.87 CNY to 35.76 CNY on July 6, 2022, due to the implementation of the annual equity distribution plan [5][8] - The board approved the granting of stock options to 365 recipients on September 15, 2022, totaling 13,101,000 options [6][23] Group 5 - On February 21, 2023, the company approved adjustments to the number of stock options granted in the 2021 plan, reducing the total from 52,092,000 to 47,733,260 due to departures and performance issues among recipients [7][9] - The exercise price for the first exercise period was set at 35.76 CNY, with 974 recipients eligible to exercise their options [7][10] Group 6 - The company held its sixth board meeting on October 20, 2023, where it approved further adjustments to the 2021 stock option incentive plan, including a reduction in the number of options from 12,785,800 to 11,482,716 due to similar reasons as previous adjustments [9][10] - The exercise price for the first exercise period was adjusted to 35.63 CNY [10][11] Group 7 - The company held its sixth board meeting on December 29, 2023, where it approved adjustments to the 2021 stock option incentive plan, reducing the number of options from 9,551,800 to 8,824,780 for the second exercise period [11][15] - The exercise price for this period was set at 35.63 CNY [11][15] Group 8 - The company held its sixth board meeting on February 5, 2026, where it approved the cancellation of stock options from the 2021 plan that were unlocked but not exercised [18][28] - The adjustments were made in accordance with the relevant regulations and were deemed to have no substantial impact on the company's financial status [32]

Core Viewpoint - The company has completed the registration capital change and obtained a new business license following the approval of its board and shareholders to reduce registered capital and amend its articles of association [1] Group 1: Company Actions - The company held its 11th board meeting on August 25, 2025, and the first extraordinary shareholders' meeting on September 10, 2025, where it approved the proposal to reduce registered capital and amend the articles of association [1] - The company has completed the necessary procedures for the change of registered capital and the filing of the amended articles of association, receiving a new business license from the Changchun Market Supervision Administration [1] Group 2: Company Information - The new registered capital of the company is 456,828,880 yuan [1] - The company is classified as a listed other joint-stock company, with its legal representative being Wu Jinhua [1] - The company was established on June 26, 1993, and is located at 2888 Nansha Street, Economic Development Zone, Changchun City [1] - The company's business scope includes manufacturing and sales of industrial control systems, mechanical and electrical equipment, smart control system integration, IoT technology services, industrial internet data services, and investment activities [1]

Group 1 - The company, Nanchang Mining Machinery Group Co., Ltd., has approved an investment of $30 million to acquire a 10% stake in Eagle Canyon Gold Limited through its wholly-owned subsidiary, NMS International Holding Pte. Ltd. [1][2][3] - The overall valuation of Eagle Canyon Gold Limited is set at $30 million, with the investment being contingent upon the completion of various preconditions, including internal restructuring and regulatory approvals [2][4][5]. - The investment aims to expand the company's overseas market presence and enhance its competitiveness in the mineral resources sector [15][18][19]. Group 2 - The transaction does not constitute a major asset restructuring or related party transaction, and it requires approval from domestic regulatory authorities for the outbound investment [2][3][17]. - The investment will provide the company with priority cooperation rights for mining projects, thereby injecting new growth momentum into its core business [18][19]. - The company plans to utilize the funds from the investment for restructuring and operational expenses related to the mining projects [5][18]. Group 3 - The investment is part of the company's strategic plan to extend its industrial chain and align with its long-term development strategy [15][18]. - The company has engaged intermediaries to conduct asset evaluations for Eagle Canyon Gold Limited, which are still ongoing [4][5]. - The investment is expected to facilitate the company's transition from traditional equipment sales to broader mining operation services, thus expanding its business ecosystem [18][19].

Core Viewpoint - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has announced that its partner STADA Arzneimittel AG's subsidiary Spirig HealthCare AG has received approval from the Swiss Medicines Agency for the marketing of tofacitinib citrate tablets, marking a significant milestone for the company's international expansion efforts [1][4]. Group 1: Product Information - The product, tofacitinib citrate, is the world's first approved oral Janus kinase inhibitor, used for treating autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2]. - The commercial name for tofacitinib citrate is Xeljanz, developed by Pfizer, which received FDA approval in November 2012 and entered the Chinese market in March 2017. The global sales forecast for 2024 is approximately $1.168 billion [2]. Group 2: Company Impact - The approval for tofacitinib citrate tablets in Switzerland establishes a solid foundation for the company's business expansion in the Swiss market and is expected to positively influence its ongoing expansion into the European market, enhancing brand recognition and market share [4]. - The collaboration with STADA on this formulation product signifies a breakthrough in the company's integrated strategy of "intermediates + specialty APIs + formulations," enriching its product line and enhancing competitive advantages [4].